Physician profile
Ignacio Bobes
NPI 1902831605
$11,818.50
in general payments reported to CMS, 2019-2025
31 companies · $3,313 in 2025
The $3,313 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,005 · 2020: $485 · 2021: $741 · 2022: $972 · 2023: $1,441 · 2024: $2,860 · 2025: $3,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,509 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,509.24 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,572.24 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,266.79 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,240.89 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,194.05 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $1,057.15 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $908.10 | 2019-2025 | Ingrezza |
| Indivior INC. | $641.94 | 2019-2025 | Sublocade, Perseris |
| Sunovion Pharmaceuticals INC. | $552.92 | 2019-2020 | |
| Almatica Pharma LLC | $523.72 | 2023-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $504.85 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $502.64 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $408.35 | 2024-2025 | Auvelity |
| Allergan, INC. | $311.91 | 2019-2020 | |
| Lundbeck LLC | $222.80 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $194.56 | 2019-2025 | Trintellix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $125.68 | 2024-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $114.57 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $102.37 | 2023-2025 | Aplenzin, Wellbutrin |
| Livanova USA, INC. | $50.38 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Ironshore Pharmaceuticals INC. | $40.11 | 2022-2023 | Jornay Pm |
| Luye Pharma (USA) LTD. | $38.40 | 2025 | Erzofri Extended-Release |
| Collegium Pharmaceutical, INC. | $37.58 | 2025 | Jornay Pm |
| Corium, LLC | $35.54 | 2023-2025 | Azstarys |
| Janssen Scientific Affairs, LLC | $35.43 | 2025 | Invega Sustenna |
| Tris Pharma INC | $30.74 | 2025 | Dyanavel Xr |
| Orexo US, INC. | $19.30 | 2023 | Zubsolv |
| Neos Therapeutics, LP | $18.78 | 2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $18.38 | 2025 | Qelbree |
| Shire North American Group INC | $16.96 | 2019 | |
| Noven Therapeutics, LLC | $16.88 | 2024 | Xelstrym, Secuado |
| Janssen Biotech, INC. | $14.49 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Bobes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.